GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » Net Change in Cash

Arecor Therapeutics (LSE:AREC) Net Change in Cash : £0.33 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Arecor Therapeutics's Net Change in Cash for the six months ended in Dec. 2023 was £-1.52 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was £0.33 Mil.

Arecor Therapeutics Net Change in Cash Historical Data

The historical data trend for Arecor Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arecor Therapeutics Net Change in Cash Chart

Arecor Therapeutics Annual Data
Trend May17 May18 May19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial 2.74 -0.18 15.42 -13.55 0.33

Arecor Therapeutics Semi-Annual Data
May18 May19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.83 -4.60 -8.95 1.85 -1.52

Arecor Therapeutics Net Change in Cash Calculation

Arecor Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-5.841+6.52+-0.18+-0.171
=0.33

Arecor Therapeutics's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1.421+0.007+-0.056+-0.047
=-1.52

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arecor Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Arecor Therapeutics (LSE:AREC) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » Net Change in Cash
Comparable Companies
LSE:ETX LSE:4BB LSE:DEST LSE:SBTX LSE:OBD LSE:SAR LSE:TRX LSE:C4XD LSE:FUM LSE:POLB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
6UI:Germany
Address
Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Website
https://www.arecor.com
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.